Long-term use of an antiinflammatory, curcumin, suppressed type 1 immunity and exacerbated visceral leishmaniasis in a chronic experimental model

Laboratory Investigation

Volumn 88, Issue 12, 2008, Pages 1329-1339

  Adapala, Nagasuresh ^a   Chan, Marion M ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiinflammatories; Curcumin; Leishmania donovani; Nitric oxide; Peroxisome proliferator activated receptor ; T helper 1 immunity

Indexed keywords

CURCUMIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CHRONIC DISEASE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE EXACERBATION; ENZYME INHIBITION; HOST SUSCEPTIBILITY; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOPATHOGENESIS; LEISHMANIA DONOVANI; LONG TERM EXPOSURE; LOW DRUG DOSE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VISCERAL LEISHMANIASIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CURCUMIN; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNITY, CELLULAR; LEISHMANIASIS, VISCERAL; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; NITRIC OXIDE SYNTHASE TYPE II; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 56649094498     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2008.90     Document Type: Article

References (42)

1. Natarajan R, Nadler JL. Lipid inflammatory mediators in diabetic vascular disease. Arterioscler Thromb Vasc Biol 2004;24:1542-1548.
2. Aggarwal BB, Kumar A, Aggarwal MS, et al. Curcumin derived from Turmeric (Curcuma longa): a spice for all seasons. In: Preuss H (eds). Phytopharmaceuticals in Cancer Chemoprevention. CRC Press: Boca Raton, 2005, pp 349-387.
3. Rapaka RS, Coates PM. Dietary supplements and related products: a brief summary. Life Sci 2006;78:2026-2032.
4. Radimer K, Bindewald B, Hughes J, et al. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol 2004;160:339-349.
5. Goldrosen MH, Straus SE. Complementary and alternative medicine; assessing the evidence for immunological benefits. Nature 2004;4:912-921.
6. Giles JT, Bathon JM. Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 2004;19:320-334.
7. Bagalas V, Kioumis I, Argyropoulou P, et al. Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept. Clin Rheumatol 2007;26:1344-1345.
8. Kelloff GJ, Boone CW, Crowell JA, et al. Chemopreventive drug development: perspectives and progress. Cancer Epidemiol Biomarkers Prev 1994;3:85-89.
9. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-2900.
10. Chan MM. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol 1995;49:1551-1556.
11. Chan MM, Huang H, Fenton MR, et al. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol 1998;55:1955-1962.
12. Brouet I, Ohshima H. Curcumin, an anti-tumour promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun 1995;206:533-540.
13. Chan MM, Ho CT, Huang HI. Effects of three dietary phytochemicals from tea, rosemary and turmeric on inflammation-induced nitrite production. Cancer Lett 1995;96:23.
14. Kang BY, Song YJ, Kim KM, et al. Curcumin inhibits Th1 cytokine profile in CD4+ T cells by suppressing interleukin-12 production in macrophages. Br J Pharmacol 1999;128:380-384.
15. Chan MM, Huang HI, Mattiacci JA, et al. Modulation of cytokine gene expression by curcumin. In: Shahidi F, Ho CT, Watanabe S (eds). Food Factors for Disease Prevention and Health Promotion. American Chemical Society Press: Washington, DC, 2003, pp 86-99.
16. Zheng S, Chen A. Disruption of transforming growth factor-beta signaling by curcumin induces gene expression of peroxisome proliferator-activated receptor-gamma in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2007;292:G113-G123.
17. Welch JS, Ricote M, Akiyama TE, et al. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFNgamma target genes in macrophages. Proc Natl Acad Sci USA 2003;100:6712-6717.
18. Rau O, Wurglics M, Paulke A, et al. Carnosic acid and carnosol, phenolic diterpene compounds of the labiate herbs rosemary and sage, are activators of the human peroxisome proliferator-activated receptor gamma. Planta Med 2006;72:881-887.
19. Wilson ME, Jeronimo SM, Pearson RD. Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog 2005;38:147-160.
20. Engwerda CR, Ato M, Kaye PM. Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis. Trends Parasitol 2004;20:524-530.
21. Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. Medical Economics Company: Montvale, NJ, 1998, pp 786-788.
22. Bora D. Epidemiology of visceral leishmaniasis in India. Natl Med J India 1999;12:62-68.
23. Krishnaswamy K. Indian functional foods: role in prevention of cancer. Nutr Rev 1996;54:S127-S131.
24. Chan MM, Adapala NS, Fong D. Curcumin overcomes the inhibitory effect of nitric oxide on Leishmania. Parasitol Res 2005;1:49-56.
25. Titus RG, Marchand M, Boon T, et al. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 1985;7:545-555.
26. Nicolas L, Prina E, Lang T, et al. Real-time PCR for detection and quantitation of Leishmania in mouse tissues. J Clin Microbiol 2002;40:1666-1669.
27. Reiner S, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995;13:151-177.
28. Trinchieri G, Scott P. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions. Res Immunol 1995;146:423-431.
29. MacMicking J, Xie Q, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997;15:323-350.
30. Green SJ, Crawford RM, Hockmeyer JT, et al. Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-γ-stimulated macrophages by induction of tumor necrosis factor-α. J Immunol 1990;145:4290-4297.
31. Liew FY, Li Y, Millott S. Tumor necrosis factor-α synergizes with IFN-γ in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol 1990;145:4306-4310.
32. Murray HW, Nathan CF. Macrophage microbicidal mechanisms in vivo: reactive nitrogen vs oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med 1999;189:741-746.
33. Murphy ML, Wille U, Villegas EN, et al. IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 2001;31:2848-2856.
34. Murray HW, Lu CM, Mauze S, et al. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun 2002;70:6284-6293.
35. Chen A, Xu J. Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol Gastrointest Liver Physiol 2005;288:G447-G456.
36. Siddiqui AM, Cui X, Wu R, et al. The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma. Crit Care Med 2006;34:1874-1882.
37. Zheng S, Chen A. Disruption of transforming growth factor-beta signaling by curcumin induces gene expression of peroxisome proliferator-activated receptor-gamma in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2007;292:G113-G123.
38. Huang JT, Welch JS, Ricote M, et al. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999;400:378-382.
39. Heinzel FP, Sadick MD, Holaday BJ, et al. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 1989;169:59-72.
40. Gao X, Kuo J, Jiang H, et al. Immunomodulatory activity of curcumin: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production in vitro. Biochem Pharmacol 2004;68:51-61.
41. Zijlstra EE, el-Hassan AM. Leishmaniasis in Sudan. Visceral leishmaniasis. Trans R Soc Trop Med Hyg 2001;95:S27-S58.
42. Saleheen D, Ali SA, Ashfaq K, et al. Latent activity of curcumin against leishmaniasis in vitro. Biol Pharm Bull 2002;25:386-389.